(Q40528924)

21 September 2017

NT-proBNP and BNP: biomarkers for heart failure management (English)

1 reference

21 September 2017

0 references

0 references

1

1 reference

21 September 2017

1 March 2004

1 reference

European Journal of Heart Failure

21 September 2017

1 reference

21 September 2017

6

1 reference

21 September 2017

3

1 reference

21 September 2017

359-363

1 reference

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Tailored therapy to hemodynamic goals for advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Biochemical detection of left-ventricular systolic dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Predictors of prognosis in patients with stable mild to moderate heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

N-terminal pro-brain natriuretic peptide A new gold standard in predicting mortality in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

BNP in hormone-guided treatment of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Bedside B-type natriuretic peptide and functional capacity in chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

B-type natriuretic peptide predicts sudden death in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Gu

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.01.008

10.1016/J.EJHEART.2004.01.008

21 January 2018

Identifiers

DOI

1 reference

21 September 2017

1 reference

PubMed ID

14987589